{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/back-pain-low-without-radiculopathy/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"6ce99d9d-152d-5b24-87b1-279f7cca5449","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 05398912-499c-4ed2-a737-1fbdd5ede5a9 --><h2>Changes</h2><!-- end field 05398912-499c-4ed2-a737-1fbdd5ede5a9 -->","summary":null,"htmlStringContent":"<!-- begin item 31bf6548-e71a-476b-a4a2-8a7b2fa5f4b0 --><!-- begin field 10058901-2ce5-401e-9f89-99784317f807 --><p><strong>November 2020 </strong>— minor update. Broken URL link updated.</p><p><strong>September 2020 </strong>— minor update. The management recommendations have been updated in line with the National Institute for Health and Care Excellence (NICE) guideline <em>Low back pain and sciatica in over 16s: assessment and management</em>. A recommendation that digital rectal examination does not need to be performed in primary care to assess for anal tone, but can be considered, has been added to the section on diagnosis in line with the National Back Pain Clinical Network document <em>Early recognition of cauda equina syndrome: a framework for assessment and referral for primary care / MSKinterface</em>. </p><p><strong>November 2018</strong> — minor update. Information added regarding making an assessment of back pain without red flag symptoms.</p><p><strong>January to March 2017 </strong>— reviewed. A literature search was conducted in January 2017 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The topic has undergone restructuring. No major changes to the recommendations have been made.</p><!-- end field 10058901-2ce5-401e-9f89-99784317f807 --><!-- end item 31bf6548-e71a-476b-a4a2-8a7b2fa5f4b0 -->","topic":{"id":"67ec8276-483f-5bd3-a1d4-abc190687cec","topicId":"9b18de7f-5dbf-47fa-b614-8130c5721d6c","topicName":"Back pain - low (without radiculopathy)","slug":"back-pain-low-without-radiculopathy","lastRevised":"Last revised in November 2020","chapters":[{"id":"d8279135-bdfb-5f8d-a638-9f5c15e8e31e","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"94f53f0f-68b9-57d2-bb9b-9205b4128d2a","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"1e14b540-8ee6-5ec6-a360-b55991b947f3","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"6ce99d9d-152d-5b24-87b1-279f7cca5449","slug":"changes","fullItemName":"Changes"},{"id":"98f67efe-dc7d-5678-ad87-be8f6369b281","slug":"update","fullItemName":"Update"}]},{"id":"4fa9a83d-808c-53a6-95a7-4906ba0762b3","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"3b4be10b-9039-5c16-9f5c-e53279f4ef3a","slug":"goals","fullItemName":"Goals"},{"id":"ac362b69-f985-5883-8d14-7b25b4cd4c92","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"1581e495-09a8-5389-a60c-1a3b417b8be7","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"5ffd119a-f7fe-5e5d-9891-d3e921d92d40","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"b051c066-56d4-5c85-8b28-98014a97b749","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"302a3eb3-4a2b-550a-89a6-cd26e0eef14a","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"bd777de4-3ef6-529d-bcbf-8bf6aa892e99","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"2e9191b9-9306-5480-be62-c1f812b84b32","slug":"definition","fullItemName":"Definition"},{"id":"810863bb-72c6-58eb-bb75-3e2f1ee214b2","slug":"prevalence","fullItemName":"Prevalence"},{"id":"b2234c07-e852-5713-8078-e978d40b2b82","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"16569068-7bdd-5aad-b47c-7e935d6c6254","slug":"prognosis","fullItemName":"Prognosis"},{"id":"a40462ae-8085-5573-a267-170ee6539bbb","slug":"complications","fullItemName":"Complications"}]},{"id":"140fe6e6-d5e6-56f6-a4ac-d1791b9a1de1","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"6540e013-bdca-57be-8415-3dacd0fd448a","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"b2bb39a7-3f14-593c-a0bb-11b6229e9193","slug":"red-flag-symptoms-signs","fullItemName":"Red flag symptoms and signs"}]},{"id":"41781ac6-3970-5128-9f67-8103d95876c0","fullItemName":"Management","slug":"management","subChapters":[{"id":"1d96563b-1a08-575c-a108-6e566028123f","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"18c68aea-1807-5bbb-a514-d9f773a881fb","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"53da469c-6c3c-5af5-b251-e252f8f3ae47","slug":"diazepam","fullItemName":"Diazepam"},{"id":"e815c8fc-c6d6-5168-aacd-92b8545caf45","slug":"nonsteroidal-anti-inflammatory-drugs","fullItemName":"Nonsteroidal anti-inflammatory drugs"},{"id":"9aaa155a-4c14-58c4-a24d-a0d7594586c1","slug":"paracetamol","fullItemName":"Paracetamol"},{"id":"f098cbb6-72ba-503d-b622-a02915fe6668","slug":"weak-opioids","fullItemName":"Weak opioids"}]},{"id":"9607837f-245f-5649-86a7-425a90fe7c11","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"c264a034-a901-521f-83d9-6e19cfe6295a","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"12ec6fad-43c6-5117-b906-d169335441b2","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"d262f13b-ed13-541d-9ca8-e7075aebd557","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"089c38f6-7158-5d2f-9683-e1e16a2e7bc9","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"62a8100d-ffe9-5e3b-8ca4-071a242c2406","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"6dbc5aaa-df51-510a-af88-268983a5b382","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"81117569-d1c8-597d-a361-fa9822c7a4f7","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"1e14b540-8ee6-5ec6-a360-b55991b947f3","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"06856ef2-0b1c-594a-9234-7f8784d39cca","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 9c51fc1d-388e-4cdf-ac3e-4dd22907ea2c --><h3>Previous changes</h3><!-- end field 9c51fc1d-388e-4cdf-ac3e-4dd22907ea2c -->","summary":null,"htmlStringContent":"<!-- begin item dd84dd97-3131-45bf-97af-b4d95b21f2c6 --><!-- begin field b82edc2c-04a1-41e2-99ca-1ad737c6acc6 --><p><strong>April 2015 </strong>—<strong> </strong>minor update. Update to the text to reflect new advice issued by the department of transport with regards to driving if taking opioids or benzodiazepines.</p><p><strong>June 2014 </strong>— minor update. Update to the text to reflect the fact that tramadol has been reclassified to a Schedule 3 controlled drug.</p><p><strong>February 2014 </strong>— reviewed. Literature searches were conducted in May 2013 and January 2014 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of this topic. The age range covered by this topic now starts from 18 years. The section on assessing for risk of long-term pain and disability in people with acute low back pain has been changed. Minor changes have been made to the recommendations for chronic back pain on physical treatments and managing poor response to treatment.</p><p><strong>July 2013 </strong>— minor update. Update to the text to reflect recent advice from the MHRA regarding diclofenac.</p><p><strong>February 2013 </strong>— minor update. The 2013 QIPP options for local implementation have been added to this topic.</p><p><strong>October 2012 </strong>— minor update. The 2012 QIPP options for local implementation have been added to this topic.</p><p><strong>May 2011</strong>— minor update. The 2010/2011 QIPP options for local implementation have been added to this topic. Issued in June 2011.</p><p><strong>June 2010 </strong>— minor update. In people at risk of cardiovascular adverse events, ibuprofen up to 1200 mg per day or naproxen up to 1000 mg per day are recommended as first-line NSAIDs. A brief description was also added to explain the controversy over the recommendation to not use injection therapies for low back pain that persists for up to one year. Issued in July 2010.</p><p><strong>November 2009 </strong>— minor update. Issued in November 2009.</p><p><strong>July to November 2009 </strong>— topic revised. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence.</p><p><strong>October 2008 </strong>— minor update. Summary of product characteristics for Neurontin<sup>® </sup>updated regarding discontinuation of gabapentin, text updated.</p><p><strong>September 2008 </strong>— converted from CKS guidance to CKS topic structure with no important changes to the recommendations.</p><p><strong>October 2005 </strong>— minor technical update. Issued in November 2005.</p><p><strong>March to July 2005 </strong>— reviewed and updated to take account of the 2004 European Guidelines for the management of low back pain. Validated in June 2005 and issued in July 2005.</p><p><strong>March 2004 </strong>— information updated for nurse prescribers.</p><p><strong>June 2003 </strong>— minor update. New advice from the British Heart Foundation on low-dose aspirin and ibuprofen added.</p><p><strong>March 2002 </strong>— updated to incorporate referral advice from the National Institute for Health and Care Excellence. Issued in April 2002.</p><p><strong>August 2001</strong>— reviewed. Validated in November 2001 and issued in April 2002.</p><p><strong>July 1999 </strong>— reviewed, and updated to take account of revised RCGP guidelines for management of acute non-specific low back pain. Validated in October 1999 and issued in January 2000.</p><!-- end field b82edc2c-04a1-41e2-99ca-1ad737c6acc6 --><!-- end item dd84dd97-3131-45bf-97af-b4d95b21f2c6 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}